

EVALUATION OF LONG TERM BIOLOGICAL ACTIVITY OF PEGASPARGASE (ONCASPAR) AFTER DILUTION IN NACL 0.9%



21st Congress of



Wien 16-18 March 2016

¹A. Meyer University Children's Hospital, Department of Pharmacy, Florence, Italy ²A. Meyer University Children's Hospital, Department of Pediatric Neurosciences, Florence, Italy ³A. Meyer University Children's Hospital, Department of Pediatric Hematology and Oncology, Florence, Italy

V.Borsi¹, F.Calderoni¹, A.Di Renzo¹, L.Scala¹, G.Scialino¹, G.La Marca², R.Ceccantini³, L.Di Simone¹, A.M.Calvani¹

BACKGROUND

Escherichia coli asparaginase is an enzyme that depletes serum levels of asparagine. It is used to treat acute lymphoblastic leukaemia and related forms of non-Hodgkin's lymphoma. Polyethylene glycosylated-asparaginase (pegaspargase), obtained by covalently attaching polyethylene glycol to the native enzyme, has been shown to sustain similar reductions in serum asparagine concentrations compared with the native enzyme. In addition, pegaspargase has a decreased immunogenicity and a prolonged half-life. The summary of product characteristics (Oncaspar) indicates that the intravascular

Evaluation of the biological activity of pegaspargase diluted to 16 UI/mL in NaCl 0.9% and stored up to 48 h at 4°C and at room temperature.


PURPOSE

infusion should be given over a period of 1-2 h but nothing is known on the long term stability and study drug A of activity of the enzyme after dilution. degradation also was

carried out.

MATERIAL AND METHODS

Samples of pegaspargase solution diluted in NaCl 0.9% were stored refrigerated at 4°C and at room temperature and protected from light.



 $\begin{array}{c} \begin{array}{c} NH_2 \\ CH_2 \\ NH_2 \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2O \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2O \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2O \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_2 \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_2 \\ \end{array} \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_3 \\ \\ H_3 \\ \end{array} \\ \begin{array}{c} H_2 \\ \\ H_3 \\ \\ H_3 \\ \end{array} \\ \begin{array}{c} H_2 \\ H_3 \\ H$


The absence of degradation products or aggregates in the two solutions was verified using size exclusion fast protein liquid chromatography (SEC-FPLC) under the following condition: Superdex 200 10/300 column; Tris buffer pH=8.6; 0.5 mL/min flow rate; 280 nm UV detection; 100 µL injection volume.

RESULTS

CALIBRATION CURVE

The assay is based on direct reaction of ammonia released with Nessler's reagent; µmoles of ammonia are

estimated by detecting the optical density of the reaction's solution at 436nm.



The variation in enzymatic activity of the diluted pegaspargase solutions compared with the fresh solution was less than 5% after 48 h, with no significant differences between storage at 4°C or at room temperature. Preservation of the enzymatic activity and the stability of the solutions evaluated will allow us to store pegaspargase for up to 48 h with costs savings and an improvement in patient compliance. A microbiological study is in progress to validate the aseptic manufacturing process in order to guarantee the sterility of the stored solutions. **Contact:** valentina.borsi@meyer.it

No conflict of interest.